Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation (original) (raw)

• Kamashev, D.E., Vitoux, D. & de Thé, H. PML/RARA-RXR oligomers mediate retinoid- and rexinoid- /cAMP in APL cell differentiation. J. Exp. Med. 199, 1163–1174 (2004).
  Article CAS Google Scholar
• van Wageningen, S. et al. Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR{alpha}. Blood 111, 1634–1643 (2008).
  Article CAS Google Scholar
• Melnick, A. & Licht, J.D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167–3215 (1999).
  CAS Google Scholar
• Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079–1082 (2002).
  Article CAS Google Scholar
• Zhu, J. et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7, 143–153 (2005).
  Article CAS Google Scholar
• Zhou, J. et al. Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc. Natl. Acad. Sci. USA 103, 9238–9243 (2006).
  Article CAS Google Scholar
• Villa, R. et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11, 513–525 (2007).
  Article CAS Google Scholar
• Zhu, J. et al. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 12, 23–35 (2007).
  Article CAS Google Scholar
• Zeisig, B.B. et al. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 12, 36–51 (2007).
  Article CAS Google Scholar
• Quignon, F., Chen, Z. & de Thé, H. Retinoic acid and arsenic: towards oncogene targeted treatments of acute promyelocytic leukaemia. Biochim. Biophys. Acta 1333, M53–M61 (1997).
  CAS PubMed Google Scholar
• Zhu, J., Lallemand-Breitenbach, V. & de The, H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20, 7257–7265 (2001).
  Article CAS Google Scholar
• Wang, Z.Y. & Chen, Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111, 2505–2515 (2008).
  Article CAS Google Scholar
• Muindi, J. et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 79, 299–303 (1992).
  CAS PubMed Google Scholar
• Nervi, C. et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 92, 2244–2251 (1998).
  CAS PubMed Google Scholar
• Zhu, J. et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RAR alpha) and oncogenic RAR alpha fusion proteins. Proc. Natl. Acad. Sci. USA 96, 14807–14812 (1999).
  Article CAS Google Scholar
• Lane, A.A. & Ley, T.J. Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell 115, 305–318 (2003).
  Article CAS Google Scholar
• vom Baur, E. et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 15, 110–124 (1996).
  Article CAS Google Scholar
• Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As(2)O(3)-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193, 1361–1372 (2001).
  Article CAS Google Scholar
• Mann, K.K. et al. Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. J. Clin. Invest. 115, 2924–2933 (2005).
  Article CAS Google Scholar
• Zhu, J. et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94, 3978–3983 (1997).
  Article CAS Google Scholar
• Lallemand-Breitenbach, V. et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10, 547–555 (2008).
  Article CAS Google Scholar
• Hayakawa, F. & Privalsky, M.L. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5, 389–401 (2004).
  Article CAS Google Scholar
• Lallemand-Breitenbach, V. et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189, 1043–1052 (1999).
  Article CAS Google Scholar
• Rego, E.M., He, L.Z., Warrell, R.P., Jr., Wang, Z.G. & Pandolfi, P.P. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc. Natl. Acad. Sci. USA 97, 10173–10178 (2000).
  Article CAS Google Scholar
• Westervelt, P. et al. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 99, 9468–9473 (2002).
  Article CAS Google Scholar
• Lallemand-Breitenbach, V., Zhu, J., Kogan, S., Chen, Z. & de The, H. Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat. Rev. Cancer 5, 821–827 (2005).
  Article CAS Google Scholar
• Shen, Z.X. et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 101, 5328–5335 (2004).
  Article CAS Google Scholar
• Estey, E. et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107, 3469–3473 (2006).
  Article CAS Google Scholar
• Shao, W. et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARalpha protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 90, 124–133 (1998).
  Article CAS Google Scholar
• Ruchaud, S. et al. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc. Natl. Acad. Sci. USA 91, 8428–8432 (1994).
  Article CAS Google Scholar
• Guillemin, M.C. et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J. Exp. Med. 196, 1373–1380 (2002).
  Article CAS Google Scholar
• Altucci, L. et al. Rexinoid-triggered differentiation and tumours selective apoptosis of AML by protein kinase-A-mediated de-subordination of RXR. Cancer Res. 65, 8754–8765 (2005).
  Article CAS Google Scholar
• Gaillard, E. et al. Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7. Proc. Natl. Acad. Sci. USA 103, 9548–9553 (2006).
  Article CAS Google Scholar
• Wang, J.C. & Dick, J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494–501 (2005).
  Article CAS Google Scholar
• Zheng, X. et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 92, 323–331 (2007).
  Article CAS Google Scholar
• He, L.Z. et al. Two critical hits for promyelocytic leukemia. Mol. Cell 6, 1131–1141 (2000).
  Article CAS Google Scholar
• He, L.-Z. et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 18, 126–135 (1998).
  Article CAS Google Scholar
• Parrella, E. et al. Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways. J. Biol. Chem. 279, 42026–42040 (2004).
  Article CAS Google Scholar
• Zhu, J., Chen, Z., Lallemand-Breitenbach, V. & de Thé, H. How acute promyelocytic leukemia revived arsenic. Nat. Rev. Cancer 2, 705–713 (2002).
  Article CAS Google Scholar
• Turhan, A.G. et al. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 85, 2154–2161 (1995).
  CAS PubMed Google Scholar
• Zheng, P.Z. et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 102, 7653–7658 (2005).
  Article CAS Google Scholar
• Lin, D.Y. et al. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 24, 341–354 (2006).
  Article CAS Google Scholar
• Ito, K. et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072–1078 (2008).
  Article CAS Google Scholar
• Tsimberidou, A.M. et al. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk. Lymphoma 47, 1062–1068 (2006).
  Article CAS Google Scholar
• Chen, G.Q. et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 10, 825–828 (1996).
  CAS PubMed Google Scholar
• Koken, M.H.M. et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 18, 1113–1118 (1999).
  Article CAS Google Scholar
• Costoya, J.A. et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat. Genet. 36, 653–659 (2004).
  Article CAS Google Scholar
• Khetchoumian, K. et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat. Genet. 39, 1500–1506 (2007).
  Article CAS Google Scholar
• Purton, L.E. et al. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J. Exp. Med. 203, 1283–1293 (2006).
  Article CAS Google Scholar
• Matthay, K.K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165–1173 (1999).
  Article CAS Google Scholar